Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07871604
PHASE4

Feasibility of Combination Therapy With Low-dose Statin and Ezetimibe in Patients With Minimal Subclinical Atherosclerosis

Sponsor: Yonsei University

View on ClinicalTrials.gov

Summary

This study aims to compare the tolerability and metabolic safety of three low-dose statin/ezetimibe combinations (rosuvastatin/ezetimibe 2.5/10 mg, atorvastatin/ezetimibe 5/10 mg, pitavastatin/ezetimibe 1/10 mg) in patients with minimal subclinical atherosclerosis identified by imaging studies (Coronary Computed Tomography Angiography, Coronary Angiography, or carotid sonography)

Key Details

Gender

All

Age Range

30 Years - 79 Years

Study Type

INTERVENTIONAL

Enrollment

300

Start Date

2026-11-10

Completion Date

2029-09-21

Last Updated

2026-10-16

Healthy Volunteers

No

Interventions

DRUG

Crezet 2.5/10mg

Participants will take 1 tablet of Rosuvastatin/ezetimibe 2.5/10mg(Crezet 2.5/10mg) orally once daily for 12 months

DRUG

Litorvazet 5/10mg

Participants will take 1 tablet of Atorvastatin/ezetimibe 5/10mg (Litorvazet 5/10mg) orally once daily for 12 months

DRUG

Baroezet 1/10mg

Participants will take 1 tablet of Pitavastatin/ezetimibe 1/10mg (Baroezet 1/10mg) orally once daily for 12 months

Locations (2)

Yongin Severance Hospital, Yonsei University College of Medicine

Yongin-si, Gyeonggi-do, South Korea

Yongin Severance Hospital, Yonsei University College of Medicine

Yongin-si, Gyeonggi-do, South Korea